Skip to main content


Fig. 2 | BMC Cancer

Fig. 2

From: Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth

Fig. 2

Nc886 expression and its correlation with promoter methylation in prostate cells. Expression levels of nc886 were determined using RT and qPCR with specific primers (see Materials and Methods) and RNAU6 was used as and endogenous control of RNA amount (A, B and C). a Expression of nc886 in 6 matched normal and tumor human prostate tissue relative to RNAU6. b Expression of nc886 relative to PrEC are presented (upper plot) and average methylation of nc886 promoter (lower plot) in prostate cancer cell lines. Methylation data was extracted from publicly available GEO datasets GSE34340, GSE62053 and GSE54758. c Expression of nc886 in prostate cancer cell lines treated with 5-Azacytidine relative to untreated cell lines (control DMSO). d Correlation between the fold change in average nc886 TSS200 methylation and DNMT3B expression in tumor vs. normal tissue, assessed in 50 matched samples of the TCGA-PRAD dataset. e Average methylation of nc886 promoter 10 CpG sites of wt HCT116 and DNMT3B KO HCT116 cell line (GEO dataset GSE51810). P-value < 0.05 t-test two-tailed. * P-value < 0.05; ** P-value < 0.01; *** P-value < 0.001; two tailed t-test. The correlation was conducted by D’Agostino-Pearson normality and nonparametric Spearman tests

Back to article page